When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VTGN - Vistgen And Relmada: Competitors In Depression Treatment
VistaGen Therapeutics Inc.
In 2017 researchers from the University of Oxford's Department of Psychiatry proclaimed no new antidepressants would likely come to market in the next decade. Despite this lousy prediction, March 2019 saw the approval of Johnson & Johnson's (JNJ) esketamine (Spravato) for treatment-resistant depression (TRD) which has brought fresh interest to the antidepressant space. In this article I take a look at two smaller companies, VistaGen Theraputics (OTC:VTGN) and Relmada Therapeutics (OTCQB:RLMD), both of which have near-term readouts from trials in major depressive disorder (NYSEARCA:MDD).